IPO Trending
SUPRIYAEQ / NSE, BSEListed

Supriya Lifescience Limited

Supriya Lifescience is a manufacturer of Active Pharmaceutical Ingredients (APIs), producing 38 APIs across therapeutic segments such as antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatics, and anti-allergics. Between FY 2017 and FY 2021, it was the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, and one of the largest exporters of Salbutamol Sulphate in FY 2021. The company exports to 86 countries, serving 1,296 customers, including 346 distributors, across Europe, Latin America, Asia, and North America. Its modern manufacturing facility in Maharashtra spans 23,806 sq. m with a reactor capacity of 547 KL/day and seven clean rooms. Supriya Lifescience has acquired an additional 12,551 sq. m plot for expansion and holds regulatory approvals from USFDA, EDQM, TGA-Australia, KFDA-Korea, PMDA-Japan, NMPA-China, and Health Canada for its API exports.

₹265 - ₹274Open
Listed Price421.00
Listing Gain+53.65%
TimelineBookbuilding IPO
Open16 Dec 2021
Close20 Dec 2021
Allotment23 Dec 2021
Listing28 Dec 2021

Quota Reservation Portions

QIBPortion: 1,91,60,585 shares
75%
Nii (hni)Portion: 38,32,116 shares
15%
RetailPortion: 25,54,744 shares
10%

Minimum Application Bracket Matrix

Retail1 lots / 54 shares
₹14,796
sHNI14 lots / 756 shares
₹2,07,144
bHNI68 lots / 3,672 shares
₹10,06,128

About the Company

Supriya Lifescience is a manufacturer of Active Pharmaceutical Ingredients (APIs), producing 38 APIs across therapeutic segments such as antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatics, and anti-allergics. Between FY 2017 and FY 2021, it was the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, and one of the largest exporters of Salbutamol Sulphate in FY 2021. The company exports to 86 countries, serving 1,296 customers, including 346 distributors, across Europe, Latin America, Asia, and North America. Its modern manufacturing facility in Maharashtra spans 23,806 sq. m with a reactor capacity of 547 KL/day and seven clean rooms. Supriya Lifescience has acquired an additional 12,551 sq. m plot for expansion and holds regulatory approvals from USFDA, EDQM, TGA-Australia, KFDA-Korea, PMDA-Japan, NMPA-China, and Health Canada for its API exports.

Company Promoters

Satish Waman Wagh
Supriya Lifescience Limited IPO Details | GMP, Allotment & Financials | IPO Trending